In recent years, Artemisinin and particularly one of its derivatives -Artesunate (ART -has become an essential alternative for treatment of both uncomplicated and severe falciparum malaria in Asia and Africa as well. Therefore, these compounds are still and inccreasingly in the focus of interest because of quick acting of this drug, is able to help even unconscious to overcome the malaria attack, when administered by injection. As an alternative, RECTOCAPS have been developed and their use is meanwhile well established. From earlier studies in children, suffering from plasmodium falciparum malaria, we obtained a high level of DHART in the blood, but as expected also a rapid decline in the levels of both DHART and ART. A second administration of ART was additionally applied 4 hours after the first administration. DHART and ART plasma levels were found to last longer on an assumed therapeutic level than those obtained after one administration only. The fever clearance and the parasitemia reduction rates were found to be effective according to this dosing regimen. In view of these findings, we decided to conduct the actual described study by administering 200 mg of ART every 3 hours (0, 3, 6 and 9 h) by the rectal route. Soft geiatine capsules (RECTOCAPS) containing 200 mg of ART GMP -type each (Artesunic acid) were administered by rectal route. Each patient received four RECTOCAPS capsules (4 x 200 mg of ART) over a 3 h period. 12 adult patients with uncomplicated malaria were selected. Age, weight, height, body temperature, parasite counts before treatment and their evolution until 96 h are determined. Blood samples were taken at short time intervals after starting with the first medication: 0, 30 min, 60 min, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, 48 h, 60 h, 72 h, 84 h, 96 hand 108 h. The aliquots of all the blood samples were used for performing parasite counts. Plasma obtained following the traditional procedure was kept at -40°C until analysis. HPLC technique with electrochemical detector was used for quantification of ART and DHART. From the blood J. Drug Metab. Pharmacokinet. 2006, No. 1 concentration values of ART and DHART, the following observation can be derived: the onset of action is observed within the first half hours, therapeutic levels of the drug obtained (89 Itg/ml ART compared to 84 ugjrnl DHART). The DHART levels are somewhat higher than those of ART (a peak concentration after 6 h starting medication of 151 ug/ml ART as compared to 276 Itg/ml DHART). The variations as a function of frequency of DHART uptake are much less marked than those observed for ART. Another finding is that after the administration, some sort of a plateau of DHART and ART is built up, lasting at least from 9 to 12 hours with DHART level of about 190 Itg/ml and ART of 90 Itg/m\. In the case of single-dose administration, the levels of both compounds were below the detection threshold after three hours. With regard to the parasite counts, although there were inter-individual variations, it should be noted that after 48 hours a high proportion of the patients (8 out of 12) was completely clear of parasites. Similar results were observed with regard to the body temperature (7 out of 12 returned to normal temperature 36 hours after starting the therapy). The findings of the study support the RECTOCAPS application principle resulting in effectiveness both for the velocity of drug uptake as well as for the height of plasma levels. Repeated administration of ART can extend the duration of therapeutic plasma levels of the drug.
INTRODUCTION
In recent years, Artemisinin and particularly one of its derivatives -Artesunate -has become an essential alternative for both uncomplicated and severe falciparum malaria in Asia and Africa.
The use of these drugs has become more frequent in other parts of the world as wellin spite of the extraordinary therapeutic success of this therapy, its use is not nearly as widespread as it deserves to be. There are a number of reasons for this, the first of which is that the cost of this medication is still relatively high for the populations in developing countries that are in need of it. However there are indications that the price will be substantially reduced in the near future. Another factor that has impeded the adoption of Artesunate is the claim made by some international bodies, that wider use of these drugs would lead to resistance of the parasite. It should be borne in mind, however, that there is sufficient evidence that the Artemisinin family of drugs has a mode of action that is totally different from that of the classicalantimalaria drugs to whichthe resistance phenomenon has been established. Furthermore, since 1985, millions of people in China and Vietnam have been treated with drugs of this family with no cases of resistance reported.
On this point, homage should be paid to our Chinese colleagues for their extraordinary discovery that they saved the lives of millions of malaria patients.
Nevertheless, the high rate of recrudescence reported by several authors (1,2,3,4) remains a problem. The Chinese schema for treatment of uncomplicated malaria by the administration at 0, 4, 24 and 48 hours have resulted in a recrudescence rate from 45 to 60 % (5). However, other studies conducted at the same period of time, have reported a recrudescence rate of only 5 % when the treatment lasted for 5 days (5). These authors suggested that another antimalarial (Mephloquine) be administered after the 3 days of treatment with artemisinin and derivatives to reduce the high rate of recrudescence..
At the time that these results were reported, no reliable pharmacokinetic data were available. It is now known that the pharmacokinetics of artemisinin and derivatives are directly related to the therapeutic effect. In one of our studies in children with plasmodium falciparum malaria, we observed not only a high level of dihydroartemisinin in the blood but also a rapid decline in the levels of dihydroartemisinin and artesunate and that 4 hours after the first administration, the level for both compounds were below the detection levels. A second administration of artesunate was given 4 hours after the first administration.
The dihydroartemisinin and artesunate values, measured 1 hr later were found to be practically the same as those obtained after the first administration, the fever clearance and the parasitemia rates were also found to be surprisly good.
In view of these very encouraging results, we decide to conduct the study reported in this paper, in which 200 mg of artesunate was administered every 3 hours (0, 3, 6 and 9 h) by rectal route (RECTOCAPS suppositories).
EXPERIMENTAL CONDITIONS AND SUBJECTS OF THE STUDY
The protocole of this study has been approuved by the local ethics committee.
12 adult patients with uncomplicated malaria were selected. Age, weight, sex, height and body temperature before start of treatment are shone Table I . Parasite counts before treatment and their evolution until 96 hrs are given in Table II. Soft gelatine ampoules (RECTOCAPS from MEPHA Company) containing 200 mg of Artesunate (Artesunic acid) were administered by rectal route. Each patient received four RECTOCAPS ampoules (4 x 200 mg of Artesunate) ever a 3 h period. Since the study was designed to establish the pharmacokinetic parameter values of Artesunate under conditions of repeated administration, blood samples were taken at the following time intervals: 60h  48h  72h  30h  48h  60h  84h  48h  36h  24h  60h  36h 0,30 min, 60 min, 3 h, 6 h, 9 h, 12 h, 24 h, 36 h, 48 h, 60 h, 72 h, 84 h, 96 h and 108 h. The aliquots of all the blood samples were used for parasite counts. Plasma obtained after traditional procedure was kept at -40°C until analysis. HPLC technique with electrochemical detector was used for quantification of Artesunate and Dihydroartemisinin. The experimental conditions (colonne, mobil phase, internal standard etc) have been described in detail in one of our previous publications (5). -r ------------------------------- 
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RESULTS AND DISCUSSION
The blood level values of artesunate and dihydroartemisinin are shown in Fig. 1 . From these results, two important observations can be made. First,that the dihydroartemisinin levels are substantially higher than those of artesunate (about 2 x higher) and also that the variations as a function of frequency are much less marked than those observed for artesunate.
The second note worthy point is that in spite of the relatively limited number of administrations, a plateau of dihydroartemisinin (of about 200 ug/ml) was obtained and this was also true for artesunate although with slightly lower values.
It should also be noted that 12 hours after this first administration of RECTOCAPS the average dihydroartemisinin level was about 200 I-lg/ml and about 100 I-lg/ml for artesunate.
These values should be considerer in the light of finding that in the case of a single administration, the levels of both compounds were below the detection threshold after only three hours.
With regard to the parasite counts, although there were inter-individual variations, it should be noted that after 48 hours most of the patients (8 out of 12) were completely clear of parasites and after 60 hours only 2 patients stilI had parasites. Similar favourable results were observed with regard to temperature (7 out of 12returned to normal temperature 36 hours after the start of therapy ( Table I) .
The same experimental protocol has been used in 8 patients with severe malaria. Although the parasite counts and the temperature values are very similar to those found in patients with uncomplicated malaria, it was unfortunately not possible to quantify artesunate and dihydroartemisinin because the analytical technique used was not adequate for blood samples with a high hemolysis rate as is the case in severe malaria patients.
The findings of this study are very encouraging, not only because the clearly show the effectiveness of repeated administration of Artesunate in the form of RECTOCAPS but also and more importantly, because they strongly suggest that it would be of great interest to conduct a further study of which the protocol would be specifically designed to investigate the effect of frequent administration on recurrency.
